Literature DB >> 16649723

Use and side-effect profile of spironolactone in a private cardiologist's practice.

Eric M Williams1, Richard E Katholi, Marcey R Karambelas.   

Abstract

BACKGROUND: The beneficial effects of spironolactone on the treatment of cardiovascular diseases are well known, but translating these benefits into private practice can be difficult because of the drug's side-effect profile. HYPOTHESIS: When patients are monitored over the long term, spironolactone can be used safely with an acceptable side-effect profile.
METHODS: We retrospectively studied 762 patients taking spironolactone over a 7-year period in a cardiologist's referral-based practice and monitored them for side effects from the medication.
RESULTS: Data were available on 762 patients. The average age of our patients when started on the medication was 67.2 +/- 0.5 years. Of these, 585 (76.8%) patients were treated for heart failure and 155 (20.3%) for hypertension. An average dose of 38.4 +/- 1.4 mg of spironolactone was used for treatment of all conditions. Of the 762 patients, 81 (10.6%) experienced side effects while using the medication; 40 had hyperkalemia (5.3%), 14 had gynecomastia (1.8%), and 15 had gastritis (2%). Of the patients with hyperkalemia, average creatinine clearance decreased from 64.6 +/- 5.8 ml/min at therapy start to 50.3 +/- 5.5 ml/min at the time of onset of side effects.
CONCLUSION: Spironolactone can be used with an acceptable side-effect profile as long as patients are monitored long-term while receiving the medication.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16649723      PMCID: PMC6654241          DOI: 10.1002/clc.4960290405

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  16 in total

Review 1.  Aldosterone in congestive heart failure.

Authors:  K T Weber
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.

Authors:  F Zannad; F Alla; B Dousset; A Perez; B Pitt
Journal:  Circulation       Date:  2000-11-28       Impact factor: 29.690

3.  Spironolactone in chronic heart failure:all's well that ends well.

Authors:  W H Wilson Tang; Gary S Francis
Journal:  J Am Coll Cardiol       Date:  2003-01-15       Impact factor: 24.094

4.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

5.  Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy.

Authors:  F J Ramires; A Mansur; O Coelho; M Maranhão; C J Gruppi; C Mady; J A Ramires
Journal:  Am J Cardiol       Date:  2000-05-15       Impact factor: 2.778

6.  Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

Authors:  C A Farquharson; A D Struthers
Journal:  Circulation       Date:  2000-02-15       Impact factor: 29.690

7.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

8.  Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.

Authors:  H Schepkens; R Vanholder; J M Billiouw; N Lameire
Journal:  Am J Med       Date:  2001-04-15       Impact factor: 4.965

9.  Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines.

Authors:  Biykem Bozkurt; Ildiko Agoston; A A Knowlton
Journal:  J Am Coll Cardiol       Date:  2003-01-15       Impact factor: 24.094

10.  Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure.

Authors:  Mariantonietta Cicoira; Luisa Zanolla; Andrea Rossi; Giorgio Golia; Lorenzo Franceschini; Giovanna Brighetti; Paolo Marino; Piero Zardini
Journal:  J Am Coll Cardiol       Date:  2002-07-17       Impact factor: 24.094

View more
  5 in total

1.  Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.).

Authors:  Chakradhari Inampudi; Sridivya Parvataneni; Charity J Morgan; Prakash Deedwania; Gregg C Fonarow; Paul W Sanders; Sumanth D Prabhu; Javed Butler; Daniel E Forman; Wilbert S Aronow; Richard M Allman; Ali Ahmed
Journal:  Am J Cardiol       Date:  2014-04-18       Impact factor: 2.778

Review 2.  Renal nerves in the maintenance of hypertension: a potential therapeutic target.

Authors:  Richard E Katholi; Krishna J Rocha-Singh; Nilesh J Goswami; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-06       Impact factor: 5.369

3.  Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments.

Authors:  Faiez Zannad; João Pedro Ferreira; Bertram Pitt
Journal:  Eur Heart J Suppl       Date:  2019-02-26       Impact factor: 1.803

Review 4.  The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer.

Authors:  José A Carlos-Escalante; Marcela de Jesús-Sánchez; Alejandro Rivas-Castro; Pavel S Pichardo-Rojas; Claudia Arce; Talia Wegman-Ostrosky
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

Review 5.  Identifying new cellular mechanisms of mineralocorticoid receptor activation in the heart.

Authors:  Morag J Young; Monica Kanki; Peter J Fuller; Jun Yang
Journal:  J Hum Hypertens       Date:  2020-07-30       Impact factor: 3.012

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.